A new research paper was published in Oncotarget's Volume 16 on January 21, 2025, titled "Assessment of cfDNA release dynamics during colorectal cancer surgery." Researchers from the University of ...

Recent advancements in liquid biopsies have demonstrated the potential of cfDNA as a universal, minimally invasive sample type in cancer prognosis, diagnosis, and prenatal testing 1. In parallel, the ...

American Journal of Transplantation position paper also highlights value of absolute quantification of dd-cfDNA as a diagnostic marker, a key ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...

Cell-free DNA (cfDNA) can act as a powerful biomarker for cancer research, from disease onset to therapy selection and minimal residual disease (MRD) measurement. Next-generation sequencing (NGS) has ...

Researchers have discovered that analyzing specific patterns of cell-free DNA (cfDNA) fragmentation in a simple urine sample can effectively diagnose and stage bladder cancer, offering a much-needed ...

Clinical information of the collected samples. (A) The age distribution of the normal group and GDM group. (B) The weight distribution of the normal group and GDM group. (C) The sample time ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the American Journal of Transplantation (AJT) published a new ...

Early and accurate detection of rejection remains a major challenge in kidney transplantation, with clinicians still relying on decades-old indicators. There is a growing demand for more sensitive, ...

High accuracy and detection to identify tumor variants from degraded and low input samples as well as samples with limited DNA abundance Library preparation kit adds to Twist’s portfolio of tools to ...